Insights on the Reproductive Genetics Global Market to 2030 - Featuring Agilent Technologies, Fulgent Genetics and Illumina Among Others

Dublin, June 11, 2021 (GLOBE NEWSWIRE) -- The "Global Reproductive Genetics Market: Focus on Procedure Type, Product Type, Technology, Application Type, Country Data (15 countries) - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Reproductive genetics is a branch of science that contributes to predicting and preventing a genetic disorder during the reproductive procedure (both natural and artificial). It refers to the genetic tests and procedures that are used to offer prospective parents any needful information about the probabilities of having a child with any specific genetic disorder.

The advancements in genomic technologies and their implementation within clinical medicine have led to an expanded usage such as carrier screening, diagnosis of genetic disorders prior to implantation, and identifying the causes of infertility.

The respective genetic testing helps in analyzing genetic material such as chromosomes, genes, DNA, RNA, and gene products for accessing genetic changes that have a likelihood of causing any genetic disease after pregnancy in either mother or child.

The global reproductive genetics market is poised to have substantial investment and growth as the demand for such testing escalates, reimbursement improves, and the technology expands to additional, novel applications.

There has been steady progress in the demand for various methods of reproductive genetic testing. For instance, there has been a global explosion in the utilization of additional non-invasive prenatal testing (NIPT) and the continuous expansion of upstream preconception testing (PGD/PGS) and downstream neonatal screening and genetic disorder testing. Further, there has been a rise in the availability of next-generation technologies and panels that allow the screening of genetic disorders at an early stage in the fetus during pregnancy. However, some of these tests are often an out-of-pocket expense for patients, but the demand for genetic information, declining cost of sequencing, and rise in mixed-ethnicity population is expected to propel the growth of the market.

Within the research report, the market has been segmented on the basis of procedure type, product type, application type, technology, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The global reproductive genetics market consists of numerous large-and small-scale manufacturers and service providers. Presently, with the increasing rate of molecular advancements and the rise in the adoption of genetic tests, there has been an expansion of opportunities for the reproductive genetics market. Some of the strategies opted by the key players within the market are new product offerings, product approvals, partnerships and alliances, mergers and acquisitions, and business expansions.

In the five years (January 2017-February 2021), the market witnessed 23 product offerings, five product approvals, 16 partnerships and alliances, nine mergers and acquisitions, and five business expansions. The increasing awareness for genetic testing with an answer for genetic abnormalities caused has majorly attributed to the growing prominence for reproductive genetic testing.

On the basis of region, North America holds the largest share in the global reproductive genetics market due to improved healthcare infrastructure, rise in awareness, and improvised reimbursement policies in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Growth Drivers

• Declining Cost of Genetic Sequencing Technologies

• Increasing Awareness and Acceptance for Genetic Testing and Screening

• Rising Emphasis on Early Detection and Prevention

• Rising Maternal Age Leading to Pregnancy Complications

Market Challenges

• Lack of Regulations

• Ethical and Social Issues

Market Opportunities

• Shifting of Reimbursement Policies toward Enhanced Genetic Testing Coverage

• Rising Funding and Innovations

• Increasing Consumer Demand

Key Companies Profiled

Agilent Technologies, Inc., BGI, CENTOGENE AG, Fulgent Genetics, Inc., F. Hoffmann-La Roche Ltd, Igenomix, Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Quest Diagnostics, QIAGEN N.V., Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

• What are the most common genetic causes of genetic defects at birth globally?

• What are the emerging technologies that can take over the current technologies for genetic testing within the global reproductive genetics market?

• How are the key market players performing research investments in the respective market?

• What are the major strategies opted by the key players for advancing in the global reproductive genetics market?

• What are the regulations pertaining to the reproductive genetics market among different regions and their impact on the respective market?

• What are the initiatives implemented by different government bodies regulating the development and commercialization of reproductive genetic tests and associated platforms?

• How has COVID-19 impacted the global reproductive genetics market?

• How will the urgency of the pandemic influence the global reproductive genetics market?

• What are the leading companies dominating the global reproductive genetics market?

• What is the reimbursement scenario of the tests offered in the global reproductive genetics market?

• Based on the procedure type, which global reproductive genetics market procedure type is anticipated to witness a massive rise in demand in the forecast period 2021-2030?

• How is each segment of the global reproductive genetics market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2030?

• How is the global reproductive genetics industry anticipated to evolve during the forecast period 2021-2030?

• What are the leading trends and consumer preferences witnessed in the global reproductive genetics market?

Key Topics Covered:

1 Product Definition

2 Scope of the Research Study

3 Research Methodology

4 Market Overview
4.1 Introduction
4.2 Test Performed During Diagnosis
4.3 Market Footprint and Growth Potential
4.4 Future Potential
4.5 Impact of COVID-19 on Global Reproductive Genetics Market
4.6 COVID-19 Affecting Supply Chain of Global Reproductive Genetics Market
4.7 Interruption in Research and Clinical Development and Commercial Operation
4.7.1 Research and Clinical Development
4.7.2 Commercial Operation and Access
4.8 Navigating Crisis Recovery and Looking to the Future

5 Global Reproductive Genetics Market: Industry Analysis
5.1 Legal and Regulatory Framework
5.1.1 Overview
5.1.1.1 Regulatory Framework in the U.S.
5.2 Appropriate Use Criteria of Carrier Screening in the U.S.
5.2.1 Carrier Screening for Familial Disease
5.2.1.1 Fragile X Syndrome
5.2.2 Carrier Screening for Common and Ethnic Genetic Diseases
5.2.2.1 Cystic Fibrosis
5.2.2.2 Spinal Muscular Atrophy
5.2.2.3 Hemoglobinopathies
5.2.2.4 Ashkenazi Jewish Carrier Screening
5.2.3 Other Ethnicities
5.2.4 Regulatory Framework in the European Union
5.2.5 Germany
5.2.6 France
5.2.7 U.K.
5.2.8 Spain
5.3 Regulations in Asia-Pacific (APAC)
5.3.1 China
5.3.2 Japan
5.3.3 South Korea

6 Patent Landscape

7 Global Reproductive Genetics Market Dynamics
7.1 Impact Analysis
7.2 Market Drivers
7.2.1 The Declining Cost of Genetic Sequencing Technologies
7.2.2 Increasing Awareness and Acceptance for Genetic Testing and Screening
7.2.3 Rising Emphasis on Early Detection and Prevention
7.2.4 Rising Maternal Age Leading to Pregnancy Complications
7.3 Market Restraints
7.3.1 Lack of regulations
7.3.2 Ethical and Social Issues
7.4 Market Opportunities
7.4.1 Shifting of Reimbursement Policies toward Enhanced Genetics Coverage
7.4.2 Rising Funding and Innovations
7.4.3 Increasing Consumer Demand

8 Global Reproductive Genetics Market: Competitive Landscape
8.1 Overview
8.2 Key Developments and Strategies
8.3 New Offerings
8.4 Synergistic Activities
8.5 Product Approval
8.6 Business Expansion
8.7 Market Share Analysis
8.8 Growth-Share Analysis

9 Global Reproductive Genetics Market (by Procedure Type), $Million, 2020-2030
9.1 Overview
9.2 Carrier Screening
9.3 Pre-Natal Screening
9.4 Pre-Implantation Genetic Testing
9.5 Infertility Genetic Testing

10 Global Reproductive Genetics Market (by Product Type), 2020-2030, ($Million)
10.1 Overview
10.2 Kits
10.3 Laboratory Developed Tests (LDT)
10.4 Reagents and Consumables

11 Global Reproductive Genetics Market (by Technology), 2020-2030, ($Million)
11.1 Next-Generation Sequencing
11.2 Polymerase Chain Reaction
11.3 In Situ Hybridization (ISH/FISH)
11.4 Microarray

12 Global Reproductive Genetics Market (by Application Type), 2020-2030, ($Million)
12.1 Overview
12.2 Aneuploidy
12.3 Structural Chromosomal Abnormality
12.4 Single Gene Disorder
12.5 Others

13 Global Reproductive Genetics Market (by Region), 2020-2030, ($Million)

14 Company Profiles
14.1 Overview
14.2 Agilent Technologies, Inc.
14.2.1 Company Overview
14.2.2 Role of Agilent Technologies, Inc. in the Global Reproductive Genetics Market
14.2.3 Financials
14.2.4 SWOT Analysis
14.3 BGI
14.3.1 Company Overview
14.3.2 Role of BGI Group in Global Reproductive Genetics Market
14.3.3 SWOT Analysis
14.4 CENTOGENE AG
14.4.1 Company Overview
14.4.2 Role of Centogene AG in the Global Reproductive Genetics Market
14.4.3 SWOT Analysis
14.5 Fulgent Genetics, Inc.
14.5.1 Company Overview
14.5.2 Role of Fulgent Genetics, Inc. in the Global Reproductive Genetics Market
14.5.3 Financials
14.5.4 SWOT Analysis
14.6 F. Hoffmann-La Roche Ltd
14.6.1 Company Overview
14.6.2 Role of F. Hoffman-LA Roche Ltd in the Global Reproductive Genetics Market
14.6.3 Financials
14.6.4 SWOT Analysis
14.7 Igenomix
14.7.1 Company Overview
14.7.2 Role of Igenomix in the Global Reproductive Genetics Market
14.7.3 SWOT Analysis
14.8 Illumina, Inc.
14.8.1 Company Overview
14.8.2 Role of Illumina, Inc. in the Global Reproductive Genetics Market
14.8.3 Financials
14.8.4 SWOT Analysis
14.9 Invitae Corporation
14.9.1 Company Overview
14.9.2 Role of Invitae Corporation in the Global Reproductive Genetics Market
14.9.3 Financials
14.9.4 SWOT Analysis
14.1 Laboratory Corporation of America Holdings
14.10.1 Company Overview
14.10.2 Role of Laboratory Corporation of America Holdings in the Global Reproductive Genetics Market
14.10.3 Financials
14.10.4 SWOT Analysis
14.11 PerkinElmer, Inc.
14.11.1 Company Overview
14.11.2 Role of PerkinElmer, Inc. in the Global Reproductive Genetics Market
14.11.3 Financials
14.11.4 SWOT Analysis
14.12 Myriad Genetics, Inc.
14.12.1 Company Overview
14.12.2 Role of Myriad Genetics, Inc. in the Global Reproductive Genetics Market
14.12.3 Financials
14.12.4 Key Insights About Financial Health of the Company
14.12.5 SWOT Analysis
14.13 OPKO Health, Inc.
14.13.1 Company Overview
14.13.2 Role of OPKO Health, Inc. in the Global Reproductive Genetics Market
14.13.3 Financials
14.13.4 SWOT Analysis
14.14 Quest Diagnostics
14.14.1 Company Overview
14.14.2 Role of Quest Diagnostics in the Global Reproductive Genetics Market
14.14.3 Financials
14.14.4 SWOT Analysis
14.15 QIAGEN N.V.
14.15.1 Company Overview
14.15.2 Role of QIAGEN N.V. in the Global Reproductive Genetics Market
14.15.3 Financials
14.15.4 SWOT Analysis
14.16 Thermo Fisher Scientific Inc.
14.16.1 Company Overview
14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Reproductive Genetics Market
14.16.3 Financials
14.16.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/hqf22r

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900